Quijano Sandra, López Antonio, Manuel Sancho Juan, Panizo Carlos, Debén Guillermo, Castilla Cristina, Antonio García-Vela José, Salar Antonio, Alonso-Vence Natalia, González-Barca Eva, Peñalver Francisco Javier, Plaza-Villa Josefa, Morado Marta, García-Marco José, Arias Jesús, Briones Javier, Ferrer Secundino, Capote Javier, Nicolás Concepción, Orfao Alberto
Servicio General de Citometría, Department of Medicine and Centro de Investigación del Cáncer (CIC; USAL/CSIC), Universidad de Salamanca, Salamanca, Spain.
J Clin Oncol. 2009 Mar 20;27(9):1462-9. doi: 10.1200/JCO.2008.17.7089. Epub 2009 Feb 17.
Here, we evaluate the sensitivity and specificity of a new 11-parameter flow cytometry (FCM) approach versus conventional cytology (CC) for detecting neoplastic cells in stabilized CSF samples from newly diagnosed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) at high risk of CNS relapse, using a prospective, multicentric study design.
Moreover, we compared the distribution of different subpopulations of CSF leukocytes and the clinico-biologic characteristics of CSF+ versus CSF-, patients, in an attempt to define new algorithms useful for predicting CNS disease.
Overall, 27 (22%) of 123 patients showed infiltration by FCM, while CC was positive in only seven patients (6%), with three other cases being suspicious (2%). CC+/FCM+ samples typically had more than 20% neoplastic B cells and/or >or= one neoplastic B cell/microL, while FCM+/CC- samples showed lower levels (P < .0001) of infiltration. Interestingly, in Burkitt lymphoma, presence of CNS disease by FCM could be predicted with a high specificity when increased serum beta2-microglobulin and neurological symptoms coexisted, while peripheral blood involvement was the only independent parameter associated with CNS disease in diffuse large B-cell lymphoma, with low predictive value.
FCM significantly improves the sensitivity of CC for the identification of leptomeningeal disease in aggressive B-NHL at higher risk of CNS disease, particularly in paucicellular samples.
在此,我们采用前瞻性、多中心研究设计,评估一种新的11参数流式细胞术(FCM)方法与传统细胞学(CC)方法在检测新诊断的具有中枢神经系统(CNS)复发高风险的侵袭性B细胞非霍奇金淋巴瘤(B-NHL)稳定脑脊液(CSF)样本中肿瘤细胞时的敏感性和特异性。
此外,我们比较了CSF白细胞不同亚群的分布以及CSF阳性与CSF阴性患者的临床生物学特征,试图定义有助于预测CNS疾病的新算法。
总体而言,123例患者中有27例(22%)经FCM检测显示有浸润,而CC仅在7例患者(6%)中呈阳性,另有3例可疑(2%)。CC+/FCM+样本通常有超过20%的肿瘤性B细胞和/或≥1个肿瘤性B细胞/微升,而FCM+/CC-样本的浸润水平较低(P <.0001)。有趣的是,在伯基特淋巴瘤中,当血清β2-微球蛋白升高和神经系统症状同时存在时,通过FCM检测CNS疾病具有较高的特异性,而在弥漫性大B细胞淋巴瘤中,外周血受累是与CNS疾病相关的唯一独立参数,但其预测价值较低。
FCM显著提高了CC在识别具有较高CNS疾病风险的侵袭性B-NHL软脑膜疾病方面的敏感性,特别是在细胞数量少的样本中。